1. Effect of dopamine D3 receptor antagonism on approach responses to food cues in overweight and obese individuals
- Author
-
Barry V. O'Neill, Pradeep J. Nathan, Emilio Merlo-Pich, Annelize Koch, Brendan P. Bradley, Massimo Bani, Edward T. Bullmore, and Karin Mogg
- Subjects
Pharmacology ,Attractiveness ,medicine.medical_specialty ,Antagonist ,Audiology ,Overweight ,medicine.disease ,Placebo ,Obesity ,Psychiatry and Mental health ,Endocrinology ,Dopamine receptor D3 ,Dopamine ,Internal medicine ,medicine ,medicine.symptom ,Antagonism ,Psychology ,medicine.drug - Abstract
Objectives. To investigate the effect of manipulating the brain dopamine system, using a D3 receptor antagonist, on approach responses to food cues in overweight and obese individuals. Methods. Twenty-six healthy overweight and obese participants were randomly assigned to receive either a single dose of dopamine D3 receptor antagonist, GSK598809 (175mg), or placebo in the first assessment session; and vice versa in the second session. Using a stimulus-response compatibility task, approach bias was indexed by response latency to move an image of a manikin towards, versus away from, pictures of food, relative to non-food stimuli. Results. Data from the first session (which were unaffected by repeated testing) indicated that approach bias scores were significantly reduced in overweight and obese participants who received GSK598809, compared with those who received placebo. Data from the second session were confounded by an effect of treatment-order and, consequently, were uninformative for the hypotheses. Conclusions. Between-subjects comparison of drug versus placebo conditions indicated that GSK598809 attenuated approach bias to food cues, which is consistent with reduction in their motivational attractiveness. Findings, albeit preliminary, concur with the view that D3 receptor antagonists may prove useful as therapeutic agents for reducing appetitive responses to food cues in obesity.
- Published
- 2012